AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on track with its development plan to deliver and install the first LIGHT system in 2019. Confidence has been enhanced greatly with integration of the first three structures, overcoming technical challenges of accelerating the proton beam. Announcement of a distribution agreement for China, and a sizeable capital increase should resolve the market’s concerns about long-term funding of this important project.
11 Dec 2017
Distribution agreement and capital increase
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Distribution agreement and capital increase
Advanced Oncotherapy Plc (AVO:LON) | 1.9 0 0.0% | Mkt Cap: 10.4m
- Published:
11 Dec 2017 -
Author:
Martin Hall -
Pages:
8
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on track with its development plan to deliver and install the first LIGHT system in 2019. Confidence has been enhanced greatly with integration of the first three structures, overcoming technical challenges of accelerating the proton beam. Announcement of a distribution agreement for China, and a sizeable capital increase should resolve the market’s concerns about long-term funding of this important project.